Brief: Sinopharm Group Expects Original Annual Caps For Years Of 2022 And 2023 Will Not Be Sufficient
March 21 (Reuters) - Sinopharm Group Co Ltd 1099.HK :
* SINOPHARM GROUP - BOARD EXPECTS ORIGINAL ANNUAL CAPS FOR
YEARS
OF 2022 AND 2023 WILL NOT BE SUFFICIENT TO MEET GROUP'S NEEDS
FOR BUSINESS DEVELOPMENT
* SINOPHARM GROUP - ON 18 MARCH 2022, BOARD PROPOSES TO
RATIFY
2021 ACTUAL TRANSACTION AMOUNTS
* SINOPHARM GROUP - PROPOSES TO REVISE ANNUAL CAPS FOR
YEARS OF
2022 & 2023 FOR TRANSACTIONS CONTEMPLATED UNDER 2020 PROCUREMENT
& SALES FRAMEWORK DEAL
Source text for Eikon: ID:
Further company coverage: 1099.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For